Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide for LID in PD Patients
NCT03987750Phase 3Withdrawn
- Sponsor
- Zambon
- Start
- Oct 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of safinamide in levodopa-induced dyskinesia (LID), sponsored by Zambon. Planned start Oct 2019; status: withdrawn.
02
Drugs
safinamide
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT03987750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987750.